Validated high performance liquid chromatographic method for simultaneous determination of rosiglitazone, cilostazol, and 3,4-dehydro-cilostazol in rat plasma and its application to pharmacokinetics

Arzneimittel-Forschung/Drug Research

Volumn 58, Issue 6, 2008, Pages 288-296

  Varanasi, V S Kanthi Kiran ^a   Veeraraghavan, Sridhar ^a   Potharaju, Suresh ^a   Thappali, R S Satheeshmanikandan ^a   Raghavan, Rashmi ^a   Vakkalanka, V S Swaroop Kumar ^a  

^a Glenmark Pharmaceuticals Limited   (India)

Author keywords

3,4 Dehydro cilostazol; Antidiabetics; CAS 122320 73 4; CAS 73963 72 1; Cilostazol; Determination in rat plasma; Drug drug interactions; HPLC UV; Pharmacokinetics; Rosiglitazone

Indexed keywords

3,4 DEHYDROCILOSTAZOL; ACETONITRILE; BUFFER; CILOSTAZOL; DEHYDROCILOSTAZOL; DRUG METABOLITE; PIOGLITAZONE; POTASSIUM DIHYDROGEN PHOSPHATE; ROSIGLITAZONE; TERT BUTYL METHYL ETHER;

ABSOLUTE RECOVERY; ACCURACY; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG DETERMINATION; DRUG STRUCTURE; FLOW RATE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INTERDAY PRECISION; INTRADAY PRECISION; LIQUID LIQUID EXTRACTION; MALE; MAXIMUM PLASMA CONCENTRATION; MOBILE PHASE; NONHUMAN; PARAMETER; PLASMA; RAT; SENSITIVITY AND SPECIFICITY; ULTRAVIOLET RADIATION; VALIDATION PROCESS;

EID: 46949095722     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1296509     Document Type: Article

References (19)

1. Meriden T. Progress with thiazolidinediones in the management of type 2 diabetes mellitus. Clin Ther. 2004;26:177-190.
2. Miller J L. Rosiglitazone approved for treatment of type 2 diabetes. Am J Health Syst Pharm. 1999;56:1292-1294.
3. Cox P J, Ryan D A, Hollis F J, Harris A M, Miller A K, Vousden M, et al. Absorption, disposition, and metabolism of rosiglitazone, a potent thiazolidinedione insulin sensitizer, in humans. Drug Metab Dispos. 2000;28:772-780.
4. Chapman T M and Goa K L. Cilostazol: a review of its use in intermittent claudication. Am J Cardiovasc Drugs. 2003;3:117-138.
5. Schror K. The pharmacology of cilostazol. Diabetes Obes Metab. 2002;4 Suppl 2:S14-19.
6. Abbas R, Chow C P, Browder N J, Thacker D, Bramer S L, Fu C J, et al. In vitro metabolism and interaction of cilostazol with human hepatic cytochrome P450 isoforms. Hum Exp Toxicol. 2000;19:178-184.
7. Akiyama H, Kudo S and Shimizu T. The metabolism of a new antithrombotic and vasodilating agent, cilostazol, in rat, dog and man. Arzneimittel- Forschung (Drug Research). 1985;35:1133-1140.
8. Bramer S L, Tata P N, Vengurlekar S S and Brisson J H. Method for the quantitative analysis of cilostazol and its metabolites in human plasma using LC/MS/MS. J Pharm Biomed Anal. 2001;26:637-650.
9. Akiyama H, Kudo S, Odomi M and Shimizu T. High-performance liquid chromatographic procedure for the determination of a new antithrombotic and vasodilating agent, cilostazol, in human plasma. J Chromatogr. 1985;338:456-459.
10. Fu C J, Tata P N, Okada K, Akiyama H and Bramer S L. Simultaneous quantitative determination of cilostazol and its metabolites in human plasma by high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl. 1999;728:251-262.
11. Tata PN.Fu CH and Bramer S L. Determination of cilostazol and its metabolites in human urine by high performance liquid chromatography. J Pharm Biomed Anal. 2001;24:381-389.
12. Tata P N, Fu C H, Browder N J, Chow P C and Bramer S L. The quantitative determination of cilostazol and its four metabolites in human liver microsomal incubation mixtures by high-performance liquid chromatography. J Pharm Biomed Anal. 1998;18:441-451.
13. Hruska M W and Frye R F. Simplified method for determination of rosiglitazone in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2004;803:317-320.
14. Kim K A and Park J Y. Simple and extractionless high-performance liquid chromatographic determination of rosiglitazone in human plasma and application to pharmacokinetics in humans. Biomed Chromatogr. 2004;18:613-615.
15. Mamidi R N, Benjamin B, Ramesh M and Srinivas N R. Simple method for the determination of rosiglitazone in human plasma using a commercially available internal standard. Biomed Chromatogr. 2003;17:417-420.
16. Mamidi R N, Chaluvadi M R, Benjamin B, Ramesh M, Katneni K, Babu A P, et al. HPLC method for the determination of rosiglitazone in human plasma and its application in a clinical pharmacokinetic study. Arzneimittel- Forschung (Drug Research). 2002;52:560-564.
17. Kolte B L, Raut B B, Deo A A, Bagool M A and Shinde D B. Liquid chromatographic method for the determination of rosiglitazone in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2003;788:37-44.
18. Kolte B L, Raut B B, Deo A A, Bagool M A and Shinde D B. Simultaneous determination of metformin in combination with rosiglitazone by reversed-phase liquid chromatography. J Chromatogr Sci. 2004;42:70-73.
19. Lin Z J, Desai-Krieger D and Shum L. Simultaneous determination of glipizide and rosiglitazone unbound drug concentrations in plasma by equilibrium dialysis and liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2004;801:265-272